Total Payments
$50,902
2024 Payments
$17,109
Companies
19
Transactions
142
Medicare Patients
17,879
Medicare Billing
$9.2M
Payment Breakdown by Category
Research$44,574 (87.6%)
Other$3,200 (6.3%)
Food & Beverage$3,049 (6.0%)
Education$39.95 (0.1%)
Gifts$38.80 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $44,574 | 10 | 87.6% |
| Honoraria | $3,200 | 2 | 6.3% |
| Food and Beverage | $3,049 | 127 | 6.0% |
| Education | $39.95 | 1 | 0.1% |
| Gift | $38.80 | 2 | 0.1% |
Payments by Type
Research
$44,574
10 transactions
General
$6,328
132 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alimera Sciences, Inc. | $48,616 | 50 | $0 (2024) |
| Genentech USA, Inc. | $463.17 | 22 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $441.17 | 13 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $236.68 | 8 | $0 (2024) |
| ABBVIE INC. | $229.41 | 9 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $140.64 | 5 | $0 (2021) |
| Alcon Vision LLC | $134.43 | 4 | $0 (2022) |
| Allergan, Inc. | $118.93 | 6 | $0 (2021) |
| Bausch & Lomb Americas Inc. | $90.86 | 4 | $0 (2023) |
| Biogen, Inc. | $87.99 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17,109 | 32 | Alimera Sciences, Inc. ($16,592) |
| 2023 | $449.84 | 23 | Alimera Sciences, Inc. ($79.82) |
| 2022 | $516.26 | 21 | Alimera Sciences, Inc. ($132.81) |
| 2021 | $3,689 | 15 | Alimera Sciences, Inc. ($3,265) |
| 2020 | $221.34 | 12 | Allergan, Inc. ($67.41) |
| 2019 | $301.01 | 15 | Alimera Sciences, Inc. ($132.35) |
| 2018 | $169.96 | 11 | OPTOS, INC. ($53.83) |
| 2017 | $28,445 | 13 | Alimera Sciences, Inc. ($28,309) |
All Payment Transactions
142 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/26/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $14.77 | General |
| Category: EYE CARE | ||||||
| 11/08/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $30.88 | General |
| Category: Ophthalmology | ||||||
| 11/06/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $14.64 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 10/23/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 10/02/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $29.09 | General |
| Category: EYE CARE | ||||||
| 09/24/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug), YUTIQ | Food and Beverage | In-kind items and services | $93.85 | General |
| Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 09/15/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $1,072.13 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 09/13/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $25.36 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/13/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $6.01 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 08/27/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $32.44 | General |
| Category: Immunology and Ophthalmology | ||||||
| 08/22/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $9.91 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 08/01/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $6,529.59 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 07/31/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $21.70 | General |
| Category: IMMUNOLOGY | ||||||
| 07/25/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $655.88 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 07/24/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $13.10 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 07/16/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $750.00 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 07/09/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $76.52 | General |
| Category: Ophthalmology | ||||||
| 06/28/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: Ophthalmology | ||||||
| 06/05/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $15.11 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 05/29/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $2,383.88 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 05/28/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $26.71 | General |
| Category: Ophthalmology | ||||||
| 05/14/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: Ophthalmology | ||||||
| 05/03/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: EYE CARE | ||||||
| 04/23/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: Ophthalmology | ||||||
| 04/09/2024 | Biogen, Inc. | BYOOVIZ (Biological) | Food and Beverage | In-kind items and services | $13.78 | General |
| Category: Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PALADIN | Alimera Sciences, Inc. | $28,150 | 2 |
| Iluvien Study | Alimera Sciences, Inc. | $16,424 | 8 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 4,209 | 28,190 | $9.0M | $2.4M |
| 2022 | 28 | 4,557 | 20,044 | $8.9M | $2.5M |
| 2021 | 27 | 4,791 | 16,408 | $7.6M | $2.2M |
| 2020 | 24 | 4,322 | 15,848 | $7.1M | $2.1M |
Total Patients
17,879
Total Services
80,490
Medicare Billing
$9.2M
Procedure Codes
102
All Medicare Procedures & Services
102 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 170 | 1,474 | $2.1M | $1.0M | 47.9% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 35 | 12,600 | $940,500 | $365,200 | 38.8% |
| J3490 | Unclassified drugs | Office | 2023 | 67 | 90 | $585,500 | $191,624 | 32.7% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 63 | 976 | $596,000 | $167,662 | 28.1% |
| 67028 | Injection of drug into eye | Office | 2023 | 429 | 1,828 | $2.0M | $158,020 | 8.0% |
| J0179 | Injection, brolucizumab-dbll, 1 mg | Office | 2023 | 16 | 558 | $267,900 | $137,962 | 51.5% |
| 92134 | Imaging of retina | Office | 2023 | 793 | 4,945 | $1.2M | $66,476 | 5.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 716 | 1,060 | $121,900 | $63,747 | 52.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 511 | 643 | $107,280 | $55,424 | 51.7% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 13 | 270 | $171,000 | $32,497 | 19.0% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 293 | 651 | $234,360 | $30,469 | 13.0% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 176 | 565 | $70,625 | $29,694 | 42.0% |
| 92250 | Photography of the retina | Office | 2023 | 539 | 1,688 | $253,200 | $21,124 | 8.3% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 19 | 20 | $64,000 | $16,661 | 26.0% |
| 67108 | Repair of detached retina with drainage and removal of eye fluid between lens and retina | Facility | 2023 | 17 | 18 | $94,500 | $15,581 | 16.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 88 | 88 | $16,280 | $9,691 | 59.5% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 104 | 284 | $77,000 | $4,804 | 6.2% |
| 67228 | Destruction of leaking blood vessels of retina using laser | Facility | 2023 | 16 | 16 | $32,000 | $4,164 | 13.0% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 19 | 19 | $30,400 | $3,179 | 10.5% |
| 67515 | Injection of drug or substance into membrane covering eyeball | Office | 2023 | 47 | 49 | $9,800 | $1,777 | 18.1% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 15 | 32 | $4,320 | $668.41 | 15.5% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 63 | 316 | $1,498 | $251.09 | 16.8% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 212 | 1,862 | $2.7M | $1.3M | 49.9% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 49 | 1,084 | $662,000 | $237,148 | 35.8% |
| 67028 | Injection of drug into eye | Office | 2022 | 458 | 2,017 | $2.2M | $178,935 | 8.2% |
About Dr. Ruben Grigorian, M.D
Dr. Ruben Grigorian, M.D is a Ophthalmology healthcare provider based in West Monroe, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/26/2007. The National Provider Identifier (NPI) number assigned to this provider is 1447440532.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ruben Grigorian, M.D has received a total of $50,902 in payments from pharmaceutical and medical device companies, with $17,109 received in 2024. These payments were reported across 142 transactions from 19 companies. The most common payment nature is "" ($44,574).
As a Medicare-enrolled provider, Grigorian has provided services to 17,879 Medicare beneficiaries, totaling 80,490 services with total Medicare billing of $9.2M. Data is available for 4 years (2020–2023), covering 102 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location West Monroe, LA
- Active Since 07/26/2007
- Last Updated 02/01/2016
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1447440532
Products in Payments
- ILUVIEN (Biological) $28,150
- ILUVIEN (Drug) $19,979
- Iluvien (Drug) $324.98
- OZURDEX (Drug) $280.93
- Syfovre (Drug) $219.85
- EYLEA (Biological) $213.99
- Lucentis (Biological) $208.06
- EYLEA HD (Biological) $195.98
- SUSVIMO (Drug) $164.91
- BEOVU (Drug) $121.89
- XIPERE (Drug) $90.86
- YUTIQ (Drug) $90.67
- Vabysmo (Drug) $90.20
- NGENUITY (Device) $67.58
- DURYSTA (Drug) $67.41
- Monaco (Device) $53.83
- Cimerli (Biological) $48.09
- None Specified (Medical Supply) $38.80
- STELLARIS (Device) $36.52
- EYLEA AFLIBERCEPT INJECTION (Biological) $31.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in West Monroe
Kim Tien Dinh, Md, MD
Ophthalmology — Payments: $4,880
Ophthalmology $4,880
Daniel Bonnette
Ophthalmology — Payments: $2,484
Ophthalmology $2,484
Dr. Thomas Parker, M.d, M.D
Ophthalmology — Payments: $1,826
Ophthalmology $1,826
Dr. Raymond Haik, M.d, M.D
Ophthalmology — Payments: $870.78
Ophthalmology $870.78
Dr. Joseph Humble, M.d, M.D
Ophthalmology — Payments: $835.32
Ophthalmology $835.32